The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 23, 2024

Conditions
Plaque Psoriasis
Interventions
DRUG

TLL018 tablets

oral tablets administered 20 mg BID and 40 mg BID for 12 weeks

Trial Locations (35)

10003

Mount Sinai, New York

10075

Sadick Research Group, New York

18249

DermDox, Sugarloaf

20850

Lawrence Green, Rockville

29407

CRCC, Charleston

32256

CNS - Jacksonville, Jacksonville

CNS - Orlando SODO, Jacksonville

33016

Sweet Hope Research Specialty, Inc, Hialeah

33071

Life Clinical Trials, Coral Springs

33122

D&H Doral Research Center LLC, Doral

33176

Anchor Medical Research, LLC (Core Clinical Trials), Miami

Reserka Research, Miami

33461

Altus Research, Lake Worth

33484

Palm Beach, DeLand

33613

ForCare Medical (CenExcel), Tampa

35244

Cahaba, Birmingham

37909

Dermatology Associates of Knoxville, Knoxville

43215

Remington-Davis, Inc., Columbus

48084

Revival Research Institute, Troy

48088

Grekin Skin, Warren

48326

Oakland Hills Dermatology, Auburn Hills

50265

Integrated Clinical Trial Services, Inc, Des Moines

55112

Minnesota Clinical Study Center, New Ulm

71201

IMA Clinical Research, Monroe

77433

Studies in Dermatology, LLC, Cypress

77479

Acclaim, Sugar Land

78213

Progressive Clinical Research Group, Inc., San Antonio

78660

Austin Institute for Clinical Research, Pflugerville

78759

Derm Research, Austin

90017

Metropolis Derm, Los Angeles

90210

Moy, Fincher, Chipps, Beverly Hills

91324

Amicis Research Center, Northridge

92117

Skin Surgical, San Diego

95815

Integrative Skin, Sacramento

02135

Metro Boston, Brighton

All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY